NervGen Pharma Corp. NGEN
—
1.94
(0.08)
(3.96%)
as of 25 Sep
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | (1,445.60%) | (1,200.23%) | (754.40%) | |
| — | (204.82%) | (229.66%) | (115.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (1,438.09%) | (801.01%) | (365.19%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.19) | (0.21) | (0.20) | |
Free Cash Flow |
(21.80) | (13.96) | (17.06) | (18.39) | |
Piotroski F-Score |
— | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(355.20%) | (76.30%) | (105.93%) | (24.47%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.44 | 0.57 | 0.41 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.19) | (0.21) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% |
Columns are period end dates